Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Temocillin versus carbapenems for urinary tract infection due to ESBL-producing Enterobacteriaceae: a multicenter matched case-control study.
Authors
Keywords
Temocillin, Carbapenems, Urinary tract infection, ESBL, Case-control study
Journal
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
Volume -, Issue -, Pages 106361
Publisher
Elsevier BV
Online
2021-05-14
DOI
10.1016/j.ijantimicag.2021.106361
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Comment on: Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study
- (2021) Christian G Giske et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Efficacy and safety of a Belgian tertiary care outpatient parenteral antimicrobial therapy (OPAT) program
- (2020) Charlotte Quintens et al. INFECTION
- Activity of temocillin and comparators against urinary Escherichia coli and Klebsiella pneumoniae from Iran
- (2020) Mohammad Rahbar et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Epidemiology, definition and treatment of complicated urinary tract infections
- (2020) Florian M. E. Wagenlehner et al. Nature Reviews Urology
- Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study
- (2020) Kévin Alexandre et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Temocillin: is this the right momentum for its global use?
- (2019) Indran Balakrishnan et al. Future Microbiology
- Current options for the treatment of infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae in different groups of patients
- (2019) B. Gutiérrez-Gutiérrez et al. CLINICAL MICROBIOLOGY AND INFECTION
- Efficacy of cefoxitin versus carbapenem in febrile male urinary tract infections caused by extended spectrum beta-lactamase–producing Escherichia coli: a multicenter retrospective cohort study with propensity score analysis
- (2019) O. Senard et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Activity of temocillin against KPC-producing Enterobacteriaceae clinical isolates
- (2019) Athanasios Tsakris et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
- (2018) Jesús Rodríguez-Baño et al. CLINICAL MICROBIOLOGY REVIEWS
- Effect of Piperacillin-Tazobactam vs Meropenem on 30-Day Mortality for Patients With E coli or Klebsiella pneumoniae Bloodstream Infection and Ceftriaxone Resistance
- (2018) Patrick N. A. Harris et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Activity of temocillin and 15 other agents, including fosfomycin and colistin, against Enterobacteriaceae in Hong Kong
- (2017) Margaret Ip et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- Temocillin (6 g daily) in critically ill patients: continuous infusion versus three times daily administration
- (2014) P.-F. Laterre et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Temocillin disc diffusion susceptibility testing by EUCAST methodology
- (2013) G. L. Vanstone et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Temocillin use in England: clinical and microbiological efficacies in infections caused by extended-spectrum and/or derepressed AmpC β-lactamase-producing Enterobacteriaceae
- (2011) Indran Balakrishnan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Clinical efficacy of temocillin
- (2009) N. D. Gupta et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started